secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001193125-25-122872
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics induces warrant exercise by Armistice, receives ~$4.3M
------------------------------------------------------------------------

- Gross proceeds of ~$4.3M from cash exercise of Series B & C warrants at reduced exercise price of $0.65/sh.
- Issues new Series D warrant for 13,160,172 shares at $0.65/sh, 5-year term, subject to stockholder approval.
- Company must file resale registration statement for Series D shares within 45 days; seeks Nasdaq approval.
- Maxim Group receives 5.25% cash fee on gross proceeds as financial advisor.
- Proceeds to be used for working capital and general corporate purposes via Rani LLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312525122872/0001193125-25-122872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312525122872/d945177d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-122872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer